Modified Lactoferricin Peptides Selectively Kill Melanoma While Sparing Normal Cells
Optimized lactoferricin-derived peptides with +9 charge and moderate hydrophobicity selectively killed melanoma cells, including in realistic 3D tumor models.
Quick Facts
What This Study Found
The researchers tested a set of modified di-peptides (doubled versions) derived from LF11, an 11-amino-acid fragment of human lactoferricin. They systematically varied length, positive charge, and hydrophobicity to find the optimal cancer-killing design.
The winners were R-DIM-P-LF11-215 and DIM-LF11-322, both with a net charge of +9 and moderate hydrophobicity. These showed the highest specific antitumor activity in standard 2D cultures and maintained their cancer-killing specificity in 3D multicellular tumor spheroids (MCTS).
One peptide, DIM-LF11-339, was highly hydrophobic and killed cancer cells in 2D but performed poorly in 3D. It could only kill cells at the outer edge of tumor spheroids, suggesting that too much hydrophobicity prevents peptides from penetrating into the center of solid tumors.
The peptides kill cancer cells by targeting phosphatidylserine, a lipid that sits on the outside of cancer cell membranes but stays hidden inside normal cell membranes. This is what gives the peptides their cancer specificity.
Key Numbers
+9 net charge optimal; moderate hydrophobicity best; 3D spheroid penetration failed for highly hydrophobic variant
How They Did This
Tested in lab dishes using melanoma cells (in vitro). Standard 2D cell cultures were used first, then 3D multicellular tumor spheroids to better mimic real tumor tissue. Cell viability, apoptosis (programmed cell death), and membrane targeting were measured. Non-cancerous cells served as specificity controls.
Why This Research Matters
Most cancer drugs also damage healthy cells. These peptides selectively target a physical difference between cancer and normal cell membranes: the location of phosphatidylserine. The 3D spheroid data is especially valuable because flat cell cultures often overpredict drug effectiveness. The finding that moderate hydrophobicity outperforms high hydrophobicity provides a clear design rule for future peptide drugs.
The Bigger Picture
Most cancer drugs damage healthy cells alongside tumors. These peptides exploit a physical difference between cancer and normal cell membranes — the location of phosphatidylserine — to achieve selectivity. This approach could lead to cancer treatments with fewer side effects.
What This Study Doesn't Tell Us
Tested only on melanoma cells in lab dishes, not in animals or humans. The 3D spheroids are more realistic than flat cultures but still lack blood vessels, immune cells, and the full complexity of real tumors. Only one cancer type (melanoma) was tested. No pharmacokinetic data on how these peptides would behave in a living body.
Questions This Raises
- ?Will these peptides work against other cancer types beyond melanoma?
- ?Can the selectivity hold up in animal models with intact immune systems?
- ?What is the optimal delivery method for systemic use?
Trust & Context
- Key Stat:
- +9 net charge was the optimal design parameter for selective melanoma killing while sparing normal cells
- Evidence Grade:
- Preliminary evidence. Cell culture results including 3D spheroids are promising but lack animal model validation.
- Study Age:
- Published in 2020. Anti-cancer peptide research has continued to advance toward clinical candidates.
- Original Title:
- Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.
- Published In:
- Biochimica et biophysica acta. Biomembranes, 1862(8), 183264 (2020)
- Authors:
- Grissenberger, Sarah, Riedl, Sabrina(3), Rinner, Beate(3), Leber, Regina, Zweytick, Dagmar
- Database ID:
- RPEP-04828
Evidence Hierarchy
Frequently Asked Questions
How do these peptides tell cancer cells from normal cells?
Cancer cells display a molecule called phosphatidylserine on their outer membrane surface, while normal cells keep it hidden inside. The peptides target this exposed molecule like a homing signal.
Why test in 3D spheroids instead of just flat cell cultures?
3D spheroids better mimic real tumors with layers of cells, limited oxygen, and barriers to drug penetration. A peptide that works in 3D is more likely to work in an actual tumor.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04828APA
Grissenberger, Sarah; Riedl, Sabrina; Rinner, Beate; Leber, Regina; Zweytick, Dagmar. (2020). Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.. Biochimica et biophysica acta. Biomembranes, 1862(8), 183264. https://doi.org/10.1016/j.bbamem.2020.183264
MLA
Grissenberger, Sarah, et al. "Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.." Biochimica et biophysica acta. Biomembranes, 2020. https://doi.org/10.1016/j.bbamem.2020.183264
RethinkPeptides
RethinkPeptides Research Database. "Design of human lactoferricin derived antitumor peptides-act..." RPEP-04828. Retrieved from https://rethinkpeptides.com/research/grissenberger-2020-design-of-human-lactoferricin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.